Release date: 2014-12-25
Recently, a research team at Kansas State University has demonstrated the use of a peptide to prevent or reduce intestinal tissue damage.
The work being carried out by the team may have far-reaching implications, including the adoption of new methods to treat heart attacks or strokes, as well as cancer. Sherry Fleming, associate professor of biology, said that therapeutic peptides (B2 glycoprotein I peptidase inhibitors) or amino acid chains developed by Kansas State University can reduce or prevent intestinal tissue damage, ie, ischemic damage, caused by reduced blood and oxygen.
When the affected tissue restores blood flow (reperfusion), the peptide is also proven to be effective, and reperfusion is usually more destructive than ischemia. When the cell is ischemic, there is a new type of molecular marker on the cell surface that actually tells the body's immune system that the cell has a problem.
However, during reperfusion, the immune system acts like a "drama queen" and it overreacts. So the researchers hope to find a way to keep the therapeutic peptide bound only to the marker (ischemic area). We have designed therapeutic peptides that do not bind arbitrarily but bind to very clear ischemic areas. There are currently no drugs available for the treatment of reperfusion ischemia, and this therapeutic peptide has been shown to reduce tissue damage and reduce animal mortality.
Compared to other potential therapeutic agents for ischemia-reperfusion, the peptide developed by Kansas State University is considered safe because it does not damage the patient's immune system. It is also more efficient and reduces manufacturing costs. If proven to be effective, the peptide will reduce tissue damage caused by heart attacks, strokes or traumatic injuries in humans and animals.
Source: Bio Valley
Flocked Swab,Oral Swab,Swab Kit,Nasal Swab
Jiangsu HXRT MD Co.,Ltd , https://www.jshxrtmed.com